Cachexia in cancer - Zeroing in on myosin

被引：37

作者：

Chamberlain, JS ^{[1
]}

机构：

[1] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA

[2] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA

[3] Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA

[4] Univ Washington, Sch Med, Senator Paul D Wellstone Muscular Dystrophy Coope, Seattle, WA USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2004年 / 351卷 / 20期

关键词：

D O I：

10.1056/NEJMcibr042889

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2124 / 2125

页数：2

共 4 条

[1] Cancer cachexia is regulated by selective targeting of skeletal muscle gene products [J].

Acharyya, S ;

Ladner, KJ ;

Nelsen, LL ;

Damrauer, J ;

Reiser, PJ ;

Swoap, S ;

Guttridge, DC .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (03) :370-378

[2] Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression [J].

Bergstrom, DA ;

Penn, BH ;

Strand, A ;

Perry, RLS ;

Rudnicki, MA ;

Tapscott, SJ .

MOLECULAR CELL, 2002, 9 (03) :587-600

[3] Cancer cachexia: Its correlations and causes [J].

Rubin, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (09) :5384-5389

[4] Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy [J].

Sandri, M ;

Sandri, C ;

Gilbert, A ;

Skurk, C ;

Calabria, E ;

Picard, A ;

Walsh, K ;

Schiaffino, S ;

Lecker, SH ;

Goldberg, AL .

CELL, 2004, 117 (03) :399-412

← 1 →